β‐Blockers in the Treatment of Hypertension: New Data, New Directions
Why the study?
Do vasodilatory beta-blockers improve metabolic and hemodynamic profiles compared to traditional beta-blockers in patients with hypertension?
Population
Patients with hypertension
Comparison
Beta-blockers, specifically traditional agents… vs Other antihypertensive classes or placebo
Design
Editorial
Authors
Discussion
Loading...
Member takes
Implication
Newer vasodilatory beta-blockers like carvedilol and nebivolol offer improved metabolic and hemodynamic profiles compared to traditional beta-blockers, potentially overcoming the limitations that have led to the demotion of traditional beta-blockers in hypertension management.
Structured PICO
Do vasodilatory beta-blockers improve metabolic and hemodynamic profiles compared to traditional beta-blockers in patients with hypertension?
P
Population
Patients with hypertension
I
Intervention
Beta-blockers, specifically traditional agents (atenolol, metoprolol) versus vasodilatory agents (carvedilol, nebivolol)
C
Comparator
Other antihypertensive classes (thiazides, ACE inhibitors, ARBs, calcium channel blockers) or placebo
O
Outcome
Cardiovascular morbidity and mortality, stroke, and metabolic outcomes
Newer vasodilatory beta-blockers like carvedilol and nebivolol offer improved metabolic and hemodynamic profiles compared to traditional beta-blockers, potentially overcoming the limitations that have led to the demotion of traditional beta-blockers in hypertension management.
Cite This Study
Weber et al. (2008) studied this question.